Kong Garheng
Known title: DirectorCIK: 0001435183
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Labcorp to Acquire OPKO Health's BioReference Assets for $722M. Labcorp has agreed to acquire select assets from OPKO Health's BioReference division for $722 million. This move expands Labcorp's capabilities in the diagnostics sector, a key area for the company's growth. The stock is currently trading near its 52-week high, reflecting investor interest in this strategic acquisition.
Transaction History
| XERS | ▲ Buy | Grant | 24,193 | $0 | 6/4/2026 | View on chart |
| LH | ▲ Buy | Option Exercise | 897 | — | 2/11/2026 | View on chart |
| XERS | ▲ Buy | Grant | 50,000 | $0 | 6/4/2025 | View on chart |
| LH | ▲ Buy | Option Exercise | 944 | — | 2/6/2025 | View on chart |
| XERS | ▲ Buy | Grant | 50,000 | $0 | 6/5/2024 | View on chart |
| XERS | ▼ Sell | Other | 6,474 | — | 3/15/2024 | View on chart |
| LH | ▲ Buy | Option Exercise | 947 | — | 2/7/2024 | View on chart |
| XERS | ▲ Buy | Grant | 42,500 | $0 | 6/7/2023 | View on chart |
| LH | ▲ Buy | Option Exercise | 742 | — | 2/11/2023 | View on chart |
| XERS | ▲ Buy | Grant | 15,000 | $0 | 6/8/2022 | View on chart |
| LH | ▲ Buy | Option Exercise | 771 | — | 2/2/2022 | View on chart |
| XERS | ▲ Buy | Grant | 50,170 | — | 10/5/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
XERS Amid Biotech Rally on Wednesday
Benzinga reported a rise in several biotech names, including TriSalus Life Sciences, Lakefront Biotherapeutics, and Editas Medicine, on Wednesday. The lift in the sector may lift XERS as well, given its position in the biotech space. XERS trades near the middle of its 52‑week range and sits above its 11‑day support at $6.17. The recent rally could provide a backdrop for further upside.
XERS Amid Biotech Rally on Wednesday. Benzinga reported a rise in several biotech names, including TriSalus Life Sciences, Lakefront Biotherapeutics, and Editas Medicine, on Wednesday. The lift in the sector may lift XERS as well, given its position in the biotech space. XERS trades near the middle of its 52‑week range and sits above its 11‑day support at $6.17. The recent rally could provide a backdrop for further upside.